2 Biotech Penny Stocks With “Strong Buy” Ratings And “Sky-Scraping Upside Potential”

2020-05-18 22_33_16-Silver Liberty in God We Trust 1978 Coin · Free Stock PhotoAnticipating that the market will continue to stage a recovery, and possibly even return to all-time highs next year, the author of today’s article notes that “investors are scanning the Street for compelling plays, hoping to snap up stocks before share prices set off on an upward trajectory. For more risk-tolerant investors, penny stocks, or names trading for less than $5 per share, are taking center stage.” As such, she proceeds to highlight two “Strong Buy” rated biotech penny stocks with “sky-scraping upside potential”. For more, CLICK HERE.

Read More

2 Of The Most Promising Stocks In The Young – But Rapidly Growing – Gene Editing Space

2020-05-16 22_17_46-WindowWhen it comes to the nascent – but rapidly growing – gene editing space, the author of today’s article notes that “sector players are rapidly making progress in combating rare or difficult to treat diseases that traditional chemical based drugs simply cannot accomplish.” With the market for gene editing therapies expected to grow by over 18% annually, he highlights two of the most promising gene editing stocks for biotech investors to consider. For more, CLICK HERE.

Read More

Cannabis’ Coronavirus Disappointment

2020-05-14 23_13_35-WindowCannabis investors who bet that marijuana stocks would benefit from an increase in demand for cannabis products during the coronavirus lockdowns have largely been disappointed. As today’s article notes, even if demand for marijuana did rise with people stuck at home, “it hasn’t translated to gains for major cannabis producers.” Is more disappointment ahead from marijuana stocks? For more, CLICK HERE.

Read More

Micro-Caps, Mega Gains?

2020-05-10 19_59_56-low angle photo of flag of U.S.A photo – Free City Image on UnsplashMorgan Stanley’s chief US equity strategist believes that stocks hit their true bottom on March 23rd – and that the current rally could well lead to a true recovery. To prepare for the next bull run, he’s advising clients to buy into small-cap stocks, so today’s article highlights “three micro-cap penny stock companies with super-low entry costs (a dollar per share or less) and huge upside potential (greater than 90% in the year to come).” For more, CLICK HERE.

Read More

3 Potential “Game-Changer” Biotech Stocks With Triple-Digit Upside Potential

2020-05-08 20_58_20-Unrecognizable chemist taking liquid with pipette from test tube in modern labor“Veteran players of the stock picking game know that biotechs are capable of delivering a win at what feels like the drop of a hat,” notes the author of today’s article, who proceeds to highlight three biotech stocks, identified by investment firm Wedbush, with the potential to be game-changers. For these three Buy-rated biotech stocks with triple-digit upside potential, CLICK HERE.

Read More

Take Advantage Of This Stock Market Anomaly – And Outperform The Market!

2020-05-05 22_27_12-WindowToday’s article examines a particular, well-established anomaly of the stock market – the short-term reversal effect – and how active traders can use a simple rotational strategy to take advantage of this anomaly and significantly outperform the market. For more on the short-term reversal anomaly, the strategy to benefit directly from it – and whether traders can still use this strategy in these unusual times – CLICK HERE.

Read More

2 Cheap Healthcare Stocks With Growth Drivers For A Rebound

2020-05-03 19_49_27-group of doctors walking on hospital hallway photo – Free Human Image on UnsplasToday’s article highlights two cheap healthcare stocks that, while having suffered so far this year, have growth drivers at hand that should set them up for rebounds going forward: “The first of these great deals, a pharmaceutical company, has a blockbuster on the market, a newer drug with growing sales, and possible drug approvals in the coming months. And the second great deal is a diagnostics player with a huge opportunity in cancer screening.” For more, CLICK HERE.

Read More

Ahead Of Q1 Earnings, Goldman Sachs Is Bullish On These 4 Biotech Stocks

2020-04-30 20_38_05-woman holding laboratory appratus photo – Free Public health Image on UnsplashWith all the attention the top-performing health care sector, and biopharmaceutical stocks in particular, are receiving, which biotech stocks are worth a look ahead of their first-quarter earnings reports? Analysts at Goldman Sachs have identified four that they are bullish on, and today’s article notes that “While their shares only suited for aggressive growth accounts with a high-risk profile, none of these companies is a proverbial one-trick pony. In addition, they all are potential takeover candidates.” For more, CLICK HERE.

Read More